Patent application number | Description | Published |
20130024943 | SYSTEM, METHOD, AND COMPUTER PROGRAM PRODUCT FOR SECURING DATA ON A SERVER BASED ON A HEURISTIC ANALYSIS - A system, method, and computer program product are provided for securing data on a server based on a heuristic analysis. In use, information associated with attempts to access data on a server is recorded. Additionally, the information is heuristically analyzed. Further, the data is secured on the server based on the heuristic analysis. | 01-24-2013 |
20130097710 | MOBILE RISK ASSESSMENT - At least one available wireless access point is identified at a particular location and a connection is established with the available wireless access point. Communication is attempted with a trusted endpoint over the wireless access point and the attempted communication with the trusted endpoint over the wireless access point is monitored to assess risk associated with the wireless access point. Results of the assessment, in some instances, can be reported to an access point risk manager and risk associated with future attempts to use the wireless access point can be assessed based at least in part on the reported assessment results. | 04-18-2013 |
20130097711 | MOBILE RISK ASSESSMENT - A query is received from a particular endpoint device identifying a particular wireless access point encountered by the particular endpoint device. Pre-existing risk assessment data is identified for the identified particular wireless access point and query result data is sent to the particular endpoint device characterizing pre-assessed risk associated with the particular wireless access point. In some instances, the query result data is generated based on the pre-existing risk assessment data. In some instances, pre-existing risk assessment data can be the result of an earlier risk assessment carried-out at least in part by an endpoint device interfacing with and testing the particular wireless access point. | 04-18-2013 |
20140250533 | MOBILE RISK ASSESSMENT - A query is received from a particular endpoint device identifying a particular wireless access point encountered by the particular endpoint device. Pre-existing risk assessment data is identified for the identified particular wireless access point and query result data is sent to the particular endpoint device characterizing pre-assessed risk associated with the particular wireless access point. In some instances, the query result data is generated based on the pre-existing risk assessment data. In some instances, pre-existing risk assessment data can be the result of an earlier risk assessment carried-out at least in part by an endpoint device interfacing with and testing the particular wireless access point. | 09-04-2014 |
Patent application number | Description | Published |
20140279454 | PERSONA BASED BILLING - A mobile device receives from a first client application a request to exchange first data over a mobile communication network. The mobile device determines whether the first client application is associated with a first persona or a second persona of a user. Upon determining the first client application is associated with the first persona, the mobile device establishes a first data connection based on a first Access Point Name (APN) network identifier with the mobile communication network and routes the first data over the first data connection. The mobile device also receives from a second client device a request to exchange second data over the mobile communication network. Upon determining the second client application is associated with the second persona, the mobile device establishes a second data connection based on a second APN network identifier with the mobile communication network and routes the second data over the second data connection. | 09-18-2014 |
20150081488 | MARKETING INCLUSION LIST MANIPULATION - A system may include a service data warehouse configured to execute an inclusion list module to perform operations including receiving opt-out data from a billing system of a subscriber network, the opt-out data associated with use of subscriber information by at least one third-party information service, receiving an eligible subscriber list from an enterprise data warehouse of the subscriber network; and generating a customer inclusion list from the eligible subscriber list and the opt-out data, the customer inclusion list including a listing of subscribers identifiers of subscribers of the subscriber network who have opted into use of the at least one third-party information service of the subscriber network. The system may further include a notification system configured to provide privacy notices to subscribers, and automatically opt the subscribers in or out of inclusion on the customer inclusion list based on subscriber receipt of the privacy notices. | 03-19-2015 |
20150081617 | OUT OF HOME MEDIA MEASUREMENT - A system may include at least one data source configured to provide network usage data indicative of the existence of communications with subscriber devices, and web and application usage data indicative of data usage of the subscriber network by the subscriber devices. The system may also include a data warehouse server configured to perform operations including correlating the network usage data and web and application usage data into subscriber-level data; associating, with the subscriber-level data, subscriber attributes indicative of a preference of the subscriber for content in a particular category of content, and profile attributes indicative of demographic characteristics of the subscriber; matching the subscriber-level data with a set of subscriber profiles, each of the set of subscriber profiles including a set of subscriber attributes and profile attributes associated with the respective subscriber profile; and aggregating the subscriber-level data into aggregate-level data according to the matching subscriber profiles. | 03-19-2015 |
Patent application number | Description | Published |
20130097141 | PRESENTING SEARCH RESULTS ANNOTATED WITH SOCIAL NETWORK CONNECTION INFORMATION - Systems, methods, and computer-readable storage media for presenting results of search queries with indications that at least a portion of such results has been endorsed by the user and/or social network connections of the user, are provided. Upon receipt of a search query, Web search results satisfying the query are determined. Satisfying search results that have been endorsed by the requesting user and/or one or more social network connections of the requesting user are identified. Upon presentation of the search results on the SERP, those results that were identified as having been endorsed by the requesting user and/or one or more social network connections of the requesting user are annotated as such. In this way, the requesting user may be able to more readily identify personally relevant results as the annotated results have been indicated to be preferences of the user and/or his or her social network connections. | 04-18-2013 |
20130097142 | PRESENTING SEARCH RESULTS ANNOTATED WITH DOMAIN ENDORSEMENTS - Systems, methods, and computer-readable storage media for presenting results of search queries with indications that at least a portion of such results has been endorsed by the user and/or social network connections of the user, are provided. Upon receipt of a search query, Web search results satisfying the query are determined. Satisfying search results that have been endorsed by the requesting user and/or one or more social network connections of the requesting user are identified. Upon presentation of the search results on the SERF, those results that were identified as having been endorsed by the requesting user and/or one or more social network connections of the requesting user are annotated as such. In this way, the requesting user may be able to more readily identify personally relevant results as the annotated results have been indicated to be preferences of the user and/or his or her social network connections. | 04-18-2013 |
20130097144 | SUPPLEMENTAL SEARCH RESULTS HAVING SOCIAL CONNECTION ENDORSEMENT DATA ON A SERP - Systems, methods, and computer-readable storage media for presenting supplemental search results having indications that identified documents have been endorsed by the user and/or social network connections of the user are provided. A search query is received and it is determined that the user's social networking data is available. Documents that have been endorsed by the user and/or social network connections of the user are searched to identify those that satisfy the input search query. The satisfying documents are assigned a relevance score to determine whether each satisfying document is relevant enough to be shown and to determine placement of the document on the SERP relative to standard search results. Upon rendering of the SERP, a supplemental search result identifying documents that were endorsed by the user and/or social network connections of the user is presented, as is an indication about which social network connection(s) of the user endorsed the document. | 04-18-2013 |
Patent application number | Description | Published |
20110312927 | Progesterone Containing Oral Dosage Forms and Related Methods - The present invention provides for progesterone containing pharmaceutical oral dosage forms and related methods. The oral dosage forms can each include an amount of progesterone as well as a pharmaceutically acceptable carrier. The oral dosage forms can be formulated to have at least one of the following characteristics: the oral dosage form produces an pregnane metabolite mean blood plasma level of less than about 1000 nmol/L; the oral dosage form produces an pregnane metabolites mean blood plasma level, after administration of single dose of progesterone composition, such that the ratio of pregnane metabolite level to parent progesterone level of less than 10:1; has a dissolution rate in vitro, when measure using a USP Type-1 dissolution apparatus in 900 mL of deionized water with 2.0% (w/v) of sodium lauryl sulfate at 100 rpm, such that the oral dosage form releases at least 10 wt % of the progesterone within the first 30 minutes and/or releases less than 45 wt % in the first 4 hours; and the oral dosage form produces a ratio of mean plasma progesterone AUC to the amount of progesterone administered of more than 1.5×10 | 12-22-2011 |
20110312928 | Progesterone Containing Oral Dosage Forms and Related Methods - The present invention provides for progesterone containing pharmaceutical oral dosage forms and related methods. The oral dosage forms can each include an amount of progesterone as well as a pharmaceutically acceptable carrier. The oral dosage forms can be formulated to have at least one of the following characteristics: the oral dosage form produces an pregnane metabolite mean blood plasma level of less than about 1000 nmol/L; the oral dosage form produces an pregnane metabolites mean blood plasma level, after administration of single dose of progesterone composition, such that the ratio of pregnane metabolite level to parent progesterone level of less than 10:1; has a dissolution rate in vitro, when measure using a USP Type-1 dissolution apparatus in 900 mL of deionized water with 2.0% (w/v) of sodium lauryl sulfate at 100 rpm, such that the oral dosage form releases at least 10 wt % of the progesterone within the first 30 minutes and/or releases less than 45 wt % in the first 4 hours; and the oral dosage form produces a ratio of mean plasma progesterone AUC to the amount of progesterone administered of more than 1.5×10−6 hr/mL:1. | 12-22-2011 |
20130029947 | PROGESTERONE CONTAINING ORAL DOSAGE FORMS AND KITS - The present invention provides for progesterone containing pharmaceutical oral dosage forms, pharmaceutical kits, and related methods. In one embodiment, an oral dosage form formulated for on-going administration is provided. The oral dosage form includes an amount of progesterone and a pharmaceutically acceptable carrier. The oral dosage form is formulated such that upon single dose administration to a non-pregnant woman in follicular phase, the oral dosage form provides a serum progesterone C | 01-31-2013 |
20130029957 | 17-Hydroxyprogesterone Ester-Containing Oral Compositions and Related Methods - The present invention provides for bioavailable oral dosage forms containing esters of 17-hydroxyprogesterone as well as related methods. The oral dosage forms can be formulated for pregnancy support and can include a therapeutically effective amount of an ester of 17-hydroxyprogesterone and a pharmaceutically acceptable carrier. In another embodiment, a pharmaceutically acceptable oral dosage form for pregnancy support is provided. The pharmaceutically acceptable oral dosage can include a therapeutically effective amount of an ester of 17-hydroxyprogesterone and a pharmaceutically acceptable carrier. The oral dosage form can, when measured using a USP Type-II dissolution apparatus in 900 mL of deionized water with 0.5 (w/v) of sodium lauryl sulfate at 50 RPM at 37° C., release at least 20 wt % of the dose of the ester of 17-hydroxyprogesterone after 60 minutes, or in the alternative release at least 20 wt % more after 60 minutes than an equivalently dosed oral dosage form without the carrier. | 01-31-2013 |
20130172381 | ORAL DOSAGE FORMS FOR OXYGEN-CONTAINING ACTIVE AGENTS AND OXYL-CONTAINING POLYMER - The disclosed invention is drawn to pharmaceutical tablets that provide delivery of active agents having at least three oxygen-containing groups, as well as a second active ingredient. Non-limiting examples of three oxygen-containing group active agents include guaifenesin, codeine, hydrocodone, and their pharmaceutically acceptable salts. In one embodiment, a pharmaceutical tablet for oral administration once every 12 hours is provided. The tablet includes a first active agent that is a tri-oxy active agent, a second active agent, and a release rate controlling non-ionic oxyl-containing hydrophilic polymer. The total oxyl content of the hydrophilic polymer in the tablet is about 4×10 | 07-04-2013 |
20130225544 | LIPOBALANCED LONG CHAIN TESTOSTERONE ESTERS FOR ORAL DELIVERY - The present disclosure is drawn to oral pharmaceutical compositions and dosage forms containing select testosterone esters and related methods. In one embodiment of the present invention, an oral pharmaceutical composition for administration to subjects in need of testosterone is provided. The composition comprises a testosterone ester and a pharmaceutically acceptable carrier. The testosterone ester can have the structure | 08-29-2013 |
20140179728 | ORAL DOSAGE FORMS FOR OXYGEN-CONTAINING ACTIVE AGENTS AND OXYL-CONTAINING POLYMER - The disclosed invention is drawn to pharmaceutical tablets that provide delivery of active agents having at least three oxygen-containing groups, as well as a second active ingredient. Non-limiting examples of three oxygen-containing group active agents include guaifenesin, codeine, hydrocodone, and their pharmaceutically acceptable salts. In one embodiment, a pharmaceutical tablet for oral administration once every 12 hours is provided. The tablet includes a first active agent that is a tri-oxy active agent, a second active agent, and a release rate controlling non-ionic oxyl-containing hydrophilic polymer. The total oxyl content of the hydrophilic polymer in the tablet is about 4×10 | 06-26-2014 |
20140179729 | ORAL DOSAGE FORMS FOR OXYGEN-CONTAINING ACTIVE AGENTS AND OXYL-CONTAINING POLYMER - The disclosed invention is drawn to pharmaceutical tablets that provide delivery of active agents having at least three oxygen-containing groups, as well as a second active ingredient. Non-limiting examples of three oxygen-containing group active agents include guaifenesin, codeine, hydrocodone, and their pharmaceutically acceptable salts. In one embodiment, a pharmaceutical tablet for oral administration once every 12 hours is provided. The tablet includes a first active agent that is a tri-oxy active agent, a second active agent, and a release rate controlling non-ionic oxyl-containing hydrophilic polymer. The total oxyl content of the hydrophilic polymer in the tablet is about 4×10 | 06-26-2014 |
20140271882 | 17-HYDROXYPROGESTERONE ESTER CONTAINING ORAL COMPOSITIONS AND RELATED METHODS - The present invention provides for bioavailable oral dosage forms containing esters of 17-hydroxyprogesterone as well as related methods. The oral dosage forms can be formulated for pregnancy support and can include a therapeutically effective amount of an ester of 17-hydroxyprogesterone and a pharmaceutically acceptable carrier. In another embodiment, a pharmaceutically acceptable oral dosage form for pregnancy support is provided. The pharmaceutically acceptable oral dosage can include a therapeutically effective amount of an ester of 17-hydroxyprogesterone and a pharmaceutically acceptable carrier. The oral dosage form can, when measured using a USP Type-II dissolution apparatus in 900 mL of deionized water with 0.5 (w/v) of sodium lauryl sulfate at 50 RPM at 37° C., release at least 20 wt % of the dose of the ester of 17-hydroxyprogesterone after 60 minutes, or in the alternative release at least 20 wt % more after 60 minutes than an equivalently dosed oral dosage form without the carrier. | 09-18-2014 |
20140288039 | LIPOBALANCED LONG CHAIN TESTOSTERONE PRODRUGS FOR ORAL DELIVERY - The present disclosure is drawn to oral pharmaceutical compositions and dosage forms containing select lipobalanced testosterone prodrugs and related methods. In one embodiment of the present invention, an oral pharmaceutical composition for administration to subjects in need of testosterone is provided. The composition comprises a lipobalanced testosterone prodrugs and a pharmaceutically acceptable carrier. | 09-25-2014 |
20140303132 | LIPOBALANCED LONG CHAIN TESTOSTERONE ESTERS FOR ORAL DELIVERY - The present disclosure is drawn to oral pharmaceutical compositions and dosage forms containing select testosterone esters and related methods. In one embodiment of the present invention, an oral pharmaceutical composition for administration to subjects in need of testosterone is provided. The composition comprises a testosterone ester and a pharmaceutically acceptable carrier. The testosterone ester can have the structure | 10-09-2014 |
20140323452 | LIPOBALANCED LONG CHAIN TESTOSTERONE ESTERS FOR ORAL DELIVERY - The present disclosure is drawn to oral pharmaceutical compositions and dosage forms containing select testosterone esters and related methods. In one embodiment of the present invention, an oral pharmaceutical composition for administration to subjects in need of testosterone is provided. The composition comprises a testosterone ester and a pharmaceutically acceptable carrier. The testosterone ester can have the structure | 10-30-2014 |
20140323453 | LIPOBALANCED LONG CHAIN TESTOSTERONE ESTERS FOR ORAL DELIVERY - The present disclosure is drawn to oral pharmaceutical compositions and dosage forms containing select testosterone esters and related methods. In one embodiment of the present invention, an oral pharmaceutical composition for administration to subjects in need of testosterone is provided. The composition comprises a testosterone ester and a pharmaceutically acceptable carrier. The testosterone ester can have the structure | 10-30-2014 |
20140377317 | 17-HYDROXYPROGESTERONE ESTER CONTAINING ORAL COMPOSITIONS AND RELATED METHODS - The present invention provides for bioavailable oral dosage forms containing esters of 17-hydroxyprogesterone as well as related methods. The oral dosage forms can be formulated for pregnancy support and can include a therapeutically effective amount of an ester of 17-hydroxyprogesterone and a pharmaceutically acceptable carrier. In another embodiment, a pharmaceutically acceptable oral dosage form for pregnancy support is provided. The pharmaceutically acceptable oral dosage can include a therapeutically effective amount of an ester of 17-hydroxyprogesterone and a pharmaceutically acceptable carrier. The oral dosage form can, when measured using a USP Type-II dissolution apparatus in 900 mL of deionized water with 0.5 (w/v) of sodium lauryl sulfate at 50 RPM at 37° C., release at least 20 wt % of the dose of the ester of 17-hydroxyprogesterone after 60 minutes, or in the alternative release at least 20 wt % more after 60 minutes than an equivalently dosed oral dosage form without the carrier. | 12-25-2014 |
20150087666 | ORAL DOSAGE FORMS FOR OXYGEN CONTAINING ACTIVE AGENTS AND OXYL-CONTAINING POLYMERS - The disclosed invention is drawn to pharmaceutical tablets that provide delivery of active agents having at least three oxygen-containing groups, a tri-oxy active agent, as well as a second active ingredient. Non-limiting examples of three oxygen-containing group active agents include guaifenesin, codeine, hydrocodone, and their pharmaceutically acceptable salts. In one embodiment, a pharmaceutical tablet for oral administration once every 12 hours is provided. The tablet includes a first active agent that is a tri-oxy active agent, a second active agent, and a release rate controlling non-ionic oxyl-containing hydrophilic polymer. The total oxyl content of the hydrophilic polymer in the tablet is from about 4×10 | 03-26-2015 |
Patent application number | Description | Published |
20100228764 | Offline Validation of Data in a Database System for Foreign Key Constraints - An aspect of the present invention performs offline validation of data in database system for foreign key constraints. In an embodiment, a foreign key constraint defined for a database system is identified and an SQL script designed to verify whether data values stored in a foreign key column of a detail table is present in a primary key column of a master table (corresponding to the identified foreign key constraint), is generated. The SQL script is executed to determine whether the data stored in the database system satisfies the identified foreign key constraint. | 09-09-2010 |
20100274912 | Data Management Between Multiple Data Sources - Presented herein are systems and methods that facilitate the portability and management of user data maintained at two or more services. In embodiments, a configurable profile management interface or interfaces are provided to a user, which enable the user to identify data elements that may be maintained across one or more services. In embodiments, a user has the ability to set precedence values by identifying which elements from which service or services should be considered as sources of truth. In embodiments, those sources of truth may be used to propagate changes to one or more services. In embodiments, the profile synchronization functionality may be incorporated within a human resources (HR) system. In embodiments, the user can also configure a schedule for transferring data, can import some or all of the data, and/or can export all or some of the data. | 10-28-2010 |
20100312592 | CONFIRMING ENFORCEMENT OF BUSINESS RULES SPECIFIED IN A DATA ACCESS TIER OF A MULTI-TIER APPLICATION - Confirming enforcement of business rules specified in a data access tier of a multi-tier enterprise application. In an embodiment, a testing tool programmatically identifies the attributes in the data access tier that are accessible from a set of higher/interface tiers and provides the identified attributes to a user using a suitable interface. The user then specifies a set of test cases based on the provided attributes, with each test case including data elements associated with respective attributes and an expected result if the data elements are sought to be stored in the respective attributes of a data storage. The testing tool determines a validation result of operation of business rules against the combination of data elements and respective attributes. The testing tool then indicates that the business rules are enforced as desired, if the validation result is the same as the expected result. | 12-09-2010 |